Literature DB >> 31154608

Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.

İsmail Demi R1, Aslı Guler2, Pınar Alarslan3, Ahmet Murat Isil2, Ozge Ucman2, Behnaz Aslanipour4, Mehmet Calan5.   

Abstract

PURPOSE: Fractalkine (FKN) is an inflammatory chemokine related to reproductive system and glucose metabolism. There is a link between FKN and steroidogenesis as FKN induces progesterone synthesis. Polycystic ovary syndrome (PCOS) is a common reproductive and metabolic disorder associated with low progesterone production and insulin resistance. We aimed to explore whether women with PCOS have any difference in FKN levels compared to women without PCOS. We also focused on determination of any association between FKN levels and hormonal-metabolic parameters in women with PCOS.
METHODS: The current research was designed as a case-control study. Eighty subjects with PCOS and 80 age- and body mass index (BMI)-matched subjects with normal menstrual cycle were taken into the study. We measured circulating FKN levels via ELISA methods.
RESULTS: Circulating FKN levels were higher in women with PCOS than controls (1.93 ± 0.61 vs. 1.22 ± 0.33 ng/ml, P< 0.001). FKN levels showed a positive correlation with body mass index (BMI), insulin resistance, inflammatory marker hs-CRP, total testosterone, and free-androgen index (FAI), whereas it showed a negative correlation with sex hormone-binding protein in women with PCOS. Linear regression analyses revealed that the link of FKN with BMI, insulin resistance, hs-CRP, and FAI was independent. Binary logistic regression analysis showed that the risk of having PCOS was associated with high levels of FKN.
CONCLUSIONS: Increased FKN levels related to insulin resistance, inflammation and androgens in women with PCOS. FKN may have an inter-related role in different pathophysiologic pathways of PCOS.

Entities:  

Keywords:  Body mass index; Fractalkine; Hyperandrogenism; Inflammation; Insulin resistance; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2019        PMID: 31154608     DOI: 10.1007/s12020-019-01972-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  30 in total

1.  CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms.

Authors:  S Goda; T Imai; O Yoshie; O Yoneda; H Inoue; Y Nagano; T Okazaki; H Imai; E T Bloom; N Domae; H Umehara
Journal:  J Immunol       Date:  2000-04-15       Impact factor: 5.422

2.  Clinical assessment of body hair growth in women.

Authors:  D FERRIMAN; J D GALLWEY
Journal:  J Clin Endocrinol Metab       Date:  1961-11       Impact factor: 5.958

3.  A new class of membrane-bound chemokine with a CX3C motif.

Authors:  J F Bazan; K B Bacon; G Hardiman; W Wang; K Soo; D Rossi; D R Greaves; A Zlotnik; T J Schall
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

4.  Association of common polymorphisms in the fractalkine receptor (CX3CR1) with obesity.

Authors:  Dave Sirois-Gagnon; Annie Chamberland; Stéphanie Perron; Diane Brisson; Daniel Gaudet; Catherine Laprise
Journal:  Obesity (Silver Spring)       Date:  2010-06-03       Impact factor: 5.002

5.  Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart.

Authors:  J K Harrison; Y Jiang; E A Wees; M N Salafranca; H X Liang; L Feng; L Belardinelli
Journal:  J Leukoc Biol       Date:  1999-12       Impact factor: 4.962

6.  Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.

Authors:  David A Ehrmann; David R Liljenquist; Kristen Kasza; Ricardo Azziz; Richard S Legro; Mahmoud N Ghazzi
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

7.  Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion.

Authors:  T Imai; K Hieshima; C Haskell; M Baba; M Nagira; M Nishimura; M Kakizaki; S Takagi; H Nomiyama; T J Schall; O Yoshie
Journal:  Cell       Date:  1997-11-14       Impact factor: 41.582

Review 8.  Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction.

Authors:  Frank González
Journal:  Steroids       Date:  2011-12-08       Impact factor: 2.668

9.  Fractalkine is expressed in the human ovary and increases progesterone biosynthesis in human luteinised granulosa cells.

Authors:  Shuo Huang; Ping Zhao; Liying Yang; Yuan Chen; Jie Yan; Enkui Duan; Jie Qiao
Journal:  Reprod Biol Endocrinol       Date:  2011-06-30       Impact factor: 5.211

10.  Fractalkine restores the decreased expression of StAR and progesterone in granulosa cells from patients with polycystic ovary syndrome.

Authors:  Shuo Huang; Yanli Pang; Jie Yan; Shengli Lin; Yue Zhao; Li Lei; Liying Yan; Rong Li; Caihong Ma; Jie Qiao
Journal:  Sci Rep       Date:  2016-07-08       Impact factor: 4.379

View more
  4 in total

1.  Impairment of endometrial decidual reaction in early pregnant mice fed with high fat diet.

Authors:  Zixuan Chen; Weike Li; Xuemei Chen; Xueqing Liu; Yubin Ding; Fangfang Li; Junlin He; Yingxiong Wang; Rufei Gao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

2.  The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis.

Authors:  Shaimaa Aboeldalyl; Cathryn James; Emaduldin Seyam; Emad Moussa Ibrahim; Hossam El-Din Shawki; Saad Amer
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

3.  Investigating the Effect of Crocus sativus (Saffron) Petal Hydro-alcoholic Extract on Ovarian Follicle, Inflammatory Markers, and Antioxidant Enzymes in Mice Model of Polycystic Ovary Syndrome.

Authors:  Fazeleh Moshfegh; Saeedeh Zafar Balanejad; Khadige Shahrokhabady; Armin Attaranzadeh
Journal:  J Reprod Infertil       Date:  2022 Jan-Mar

Review 4.  The Disorders of Endometrial Receptivity in PCOS and Its Mechanisms.

Authors:  Nan-Xing Jiang; Xue-Lian Li
Journal:  Reprod Sci       Date:  2021-05-27       Impact factor: 2.924

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.